BRIEF—Sino-American biotech CBT Pharmaceuticals to collaborate with CrystalGenomics

Sino-American biotech CBT Pharmaceuticals is to collaborate with South Korea’s CrystalGenomics to develop an investigational combination therapy of CBT-501 and CG200745 in solid tumors.

A Phase Ib/II study is expected to be initiated by the end of this year. The firms have agreed to share development of the combo and commercialization, if successful.

CrystalGenomics chief exec Joong Myung Cho said: "We are excited to work with the CBT team, who are uniquely qualified to accelerate development of our novel HDAC inhibitor in combination with CBT-501, a differentiated anti-PD1 antibody.”